Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (02/02/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

This summary was comprehensively reviewed.

General Information About Childhood Non-Hodgkin Lymphoma (NHL)

Added text to state that U.S. transplant and cancer registries show that posttransplant lymphoproliferative disease (PTLD) accounts for about 3% of all pediatric NHL diagnoses; and that 65% of PTLDs are diffuse large B-cell lymphoma histology, and 9% are Burkitt histology (cited Yanik et al. as reference 9).

Revised text to state that other studies found that a positive minimal residual disease (MRD) at the end of induction was not prognostic, possibly because of the low number of relapses in patients with disease detected in blood or marrow at diagnosis (cited Shiramizu et al. as reference 23).

Revised text to state that studies using the dose-adjusted (DA)–EPOCH protocol (etoposide, prednisone, vincristine, and doxorubicin) with rituximab have reported an event-free survival higher than 80% (cited Giulino-Roth et al. as reference 41).

Treatment Option Overview for Childhood NHL

Revised Table 3 to update the treatment options for childhood NHL.

Aggressive Mature B-cell NHL

Revised Table 5 to update the standard treatment options for Burkitt and Burkitt-like lymphoma/leukemia and diffuse large B-cell lymphoma.

Added CYVE (high-dose cytarabine and etoposide) as a treatment option for relapsed group A and group B Burkitt and Burkitt-like lymphoma/leukemia and diffuse large B-cell lymphoma.

Added text about the results of a Japanese Pediatric Leukemia/Lymphoma Study Group trial that treated 28 patients with R-ICE (ifosfamide, carboplatin, and etoposide plus rituximab) (cited Osumi et al. as reference 35). Also added text about the results of a retrospective review of patients with relapsed disease who were treated on the LMB-89, LMB-96, and LMB-2001 trials.

Added text about the results of a multicenter, retrospective study of 38 pediatric patients and 118 adult patients treated with the DA-EPOCH-R regimen (cited Giulino-Roth et al. as reference 61).

Anaplastic Large Cell Lymphoma

Added brentuximab and crizotinib as treatment options for recurrent anaplastic large cell lymphoma.

Added text to state that for patients who achieved a complete remission, 5-year progression-free survival was 69% for those who received a transplant and 48% for those who did not receive a transplant; the difference was not statistically significant (cited Pro et al. as reference 37).

Lymphoproliferative Disease Associated With Immunodeficiency in Children

Added text to state that U.S. transplant and cancer registries show that PTLD accounts for about 3% of all pediatric NHL diagnoses; and that 65% of PTLDs are diffuse large B-cell lymphoma histology, and 9% are Burkitt histology (cited Yanik et al. as reference 14).

Rare NHL Occurring in Children

Added chemotherapy with or without rituximab as a treatment option for marginal zone lymphoma (mucosa-associated lymphoid tissue [MALT] lymphoma).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Rare NHL Occurring in Children

Next section >
About This PDQ Summary